当前位置: 首页 > 期刊 > 《上海医药》 > 2018年第17期
编号:13296789
早期血管性认知功能障碍生物标志物的研究进展(7)
http://www.100md.com 2018年6月15日 《上海医药》 2018年第17期
     [51] Jia JP, Meng R, Sun YX, et al. Cerebrospinal fluid tau, Aβ1-42 and inflammatory cytokines in patients with Alzheimer’s disease and vascular dementia [J]. Neurosci Lett, 2005, 383(1-2): 12-16.

    [52] Stefani A, Bernardini S, Panella M, et al. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis [J]. J Neurol Sci, 2005, 237(1-2): 83-88.

    [53] Paraskevas GP, Kapaki E, Papageorgiou SG, et al. CSF biomarker profile and diagnostic value in vascular dementia[J]. Eur J Neurol, 2009, 16(2): 205-211.

    [54] Cavedo E, Lista S, Khachaturian Z, et al. The road ahead to cure Alzheimer’s disease: development of biological markers and neuroimaging methods for prevention trials across all stages and target populations [J]. J Prev Alzheimers Dis, 2014, 1(3): 181-202.

    [55] Tato RE, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type [J]. J Neurol Neurosurg Psychiatry, 1995, 59(3): 280-283.

    [56] Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study [J]. J Neurol Neurosurg Psychiatry, 1998, 64(3): 298-305., http://www.100md.com(毛蕾 付饶 马天君 尹又)
上一页1 2 3 4 5 6 7